Biosketch
Dr. Vella comes from Ireland where he received his medical degree and doctoral thesis from the National University of Ireland and was licensed by the Royal Colleges of Physicians and Surgeons. His Internship was spent at Beaumont Hospital, in Dublin, and his Residency at Boston City Hospital. In 1998 he completed a research Fellowship in Transplantation Immunobiology at Harvard Medical School, and in 1999 a clinical Fellowship in the Renal Division at Brigham and Women’s Hospital and Massachusetts General Hospital, Boston. He was awarded Fellowships of the Royal College of Physicians in Ireland in 2002, and the American College of Physicians in 2003. He is an Assistant Professor of Medicine at the University of Vermont School of Medicine and on the Faculty in the Dept. of Biochemistry, Microbiology and Molecular Biology, at the University of Maine. He is an Attending Physician in the Division of Nephrology, Maine Medical Center, and the Medical Director of Renal Transplantation at the Maine Transplant Program in Portland, ME. He serves as an Associate Editor, NephSAP (Transplantation), the Chairman, Medical Advisory Board, National Kidney Foundation, and on the Editorial Board of Faculty of 1000, Transplantation. In addition, he is Chairman of the Patient Education Committee of the American Society of Transplantation.
|
Selected
Publications
Vella JP, O’Neill D, Atkins N, Donohoe J.F, Walshe J. Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrology Dialysis and Transplantation 1998;13(8):2027-32
Murphy B, Magee C, Alexander SI, Waaga AM, Snoeck H, Vella JP, Carpenter CB, Sayegh MH. Inhibition of allorecognition by a human class II MHC derived peptide through the induction of apoptosis. J Clin Invest 1999; 103(6):859-867
McDermott MF, Aksentijevich I, Galon J, McDermott E, Ogunkolade BW, Centola M, Mansfield E, Gadina M, Karenko L, Pettersson T, McCarthy J, Frucht DM, Aringer M, Torosyan Y, Teppo AM, Wilson M, Raatikainen M, Wan T, Todd I, Wood G, Schlimgen R, Kumarajeewa TR, Cooper SM, Vella JP, Amos C, Mulley J, Quane KA, Molloy G, Ranki A, Powell RJ, Hitman GA, O’Shea JJ and Kastner DL. Germline mutations in the extracellular domains of the 55 kDa TNF receptor (TNFR1) define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133-144
Vella JP, Magee C, Vos L, Womer K, Rennke H, Carpenter CB, Hancock W, Sayegh MH. Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides. Transplantation 1999; 67:1-10
Womer K, Vella JP, Sayegh MH. Chronic Allograft Dysfunction: Mechanisms and Newer Approaches to Management. Seminars Nephrology 2000; 20:126-137
Waaga AM, Gasser M, Kist-Van Holthe JE, Najafian N, Muller A, Vella JP, et al. Regulatory functions of self-restricted MHC class II allopeptide- specific Th2 clones in vivo. J Clin Invest 2001;107(7):909-16.
Vannorsdall M,Thomas S, Smith RP, Zimmerman R, Christman R, Vella JP. “Human granulocytic ehrlichiosis in a renal allograft recipient: review of the clinical spectrum of disease in solid organ transplant patients”. Transpl Inf Dis 2002 4:97-101
Harris S, Himmelfarb J, Vella JP. Prospective evaluation of T cell subsets and peripheral blood cytokines in renal transplantation: differential effects of alternate immunosuppressive protocols. AJT 2004. In Press
Vella JP. Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant 2004:4; 1731
Bennett W, Vella JP. Transplantation NephSAP. J Am Soc Nephrol Vol 4, No.1: Jan 2005 |
